2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

9:00AM-11:00AM: Abstract Number: 1247

Pharmacist-Managed Titration of Urate-Lowering Therapy to Streamline Gout Management

Measures and Measurement of Healthcare Quality Poster II

9:00AM-11:00AM: Abstract Number: 1050

Pharmacokinetic and pharmacodynamic modelling of the novel anti-ADAMTS-5 nanobody M6495 using the neo-epitope ARGS as a biomarker

Osteoarthritis and Joint Biology – Basic Science Poster I

9:00AM-11:00AM: Abstract Number: 1728

Pharmacokinetics of Cyclophosphamide in Scleroderma Treated By Cyclophosphamide Versus Transplantation

Systemic Sclerosis and Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1414

Pharmacovigilance of Biologics for Systemic Juvenile Idiopathic Arthritis Patients By the German Biologics Registry

Pediatric Rheumatology – Clinical Poster II: Autoinflammatory Disorders, Scleroderma, and Miscellaneous

9:00AM-11:00AM: Abstract Number: 1076

Phospholipase C-eta2, As a C2 Domain-Containing Protein, Regulate Aggressiveness of Fibroblast‐like Synoviocytes and Ameliorate Arthritis in Experimental Animal Models of Rheumatoid Arthritis

Rheumatoid Arthritis – Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1006

Physical Activity at Lower Intensities Reduces Localized IL-1b in a Murine Model of Gout By Systemically Down-Regulating TLR2 Expression on Circulating Neutrophils and Suppressing CXCL1 Expression

Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 1002

Pkcα Deficiency Protected Mice from UVB Induced-Skin Inflammation through Attenuation of Neutrophil Netosis

Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 1762

Plasma iC3b Level As a Biomarker of Disease Relapse in ANCA-Associated Vasculitis

Vasculitis – ANCA-Associated Poster I

9:00AM-11:00AM: Abstract Number: 1079

Plasma Metabolomic Analysis Combined with Transcriptome Data Has Revealed the Importance of Amino Acids Homeostasis in SLE Pathogenesis

Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1460

Plasma Mir-146a-5p Associates with Beneficial Body Composition and Plasma Metabolic Profiles in Rheumatoid Arthritis

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1123

Plasmacytoid Dendritic Cells in Bronchoalveolar Lavage Correlate with Pulmonary Artery Diameter and Infiltrate Perivascular Areas in the Lungs from Patients with Systemic Sclerosis Associated Pulmonary Hypertension

Systemic Sclerosis and Related Disorders – Basic Science Poster II

9:00AM-11:00AM: Abstract Number: 1023

Plasmacytoid Dendritic Cells That Infiltrate the Lungs Produce Profibrotic Cytokines and Chemokines in Bleomycin-Induced Model of Systemic Sclerosis

Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 994

Platelet Derived Growth Factor Receptors (PDGFRs) and Their Implication in Inflammatory Arthritis

Cytokines and Cell Trafficking Poster

9:00AM-11:00AM: Abstract Number: 1241

Pneumococcal Vaccination Quality Improvement Initiative within a Rheumatology Clinic at an Academic Medical Center

Infection-related Rheumatic Disease Poster – ARHP

9:00AM-11:00AM: Abstract Number: 1710

Polypharmacy in Older Adults with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].